SG11201407322QA - Compositions and methods for the treatment of multiple sclerosis - Google Patents

Compositions and methods for the treatment of multiple sclerosis

Info

Publication number
SG11201407322QA
SG11201407322QA SG11201407322QA SG11201407322QA SG11201407322QA SG 11201407322Q A SG11201407322Q A SG 11201407322QA SG 11201407322Q A SG11201407322Q A SG 11201407322QA SG 11201407322Q A SG11201407322Q A SG 11201407322QA SG 11201407322Q A SG11201407322Q A SG 11201407322QA
Authority
SG
Singapore
Prior art keywords
international
formula
compositions
publication
multiple sclerosis
Prior art date
Application number
SG11201407322QA
Other languages
English (en)
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of SG11201407322QA publication Critical patent/SG11201407322QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/04Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
SG11201407322QA 2012-05-23 2013-05-16 Compositions and methods for the treatment of multiple sclerosis SG11201407322QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2063CH2012 2012-05-23
PCT/IB2013/054012 WO2013175359A2 (en) 2012-05-23 2013-05-16 Compositions and methods for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
SG11201407322QA true SG11201407322QA (en) 2014-12-30

Family

ID=54193694

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407322QA SG11201407322QA (en) 2012-05-23 2013-05-16 Compositions and methods for the treatment of multiple sclerosis

Country Status (9)

Country Link
US (1) US9580383B2 (de)
EP (1) EP2852569B1 (de)
JP (1) JP2015518854A (de)
CN (1) CN104603097A (de)
AU (1) AU2013264896A1 (de)
CA (1) CA2873098A1 (de)
SG (1) SG11201407322QA (de)
WO (1) WO2013175359A2 (de)
ZA (1) ZA201408062B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651962T3 (es) * 2013-12-05 2018-01-30 Ratiopharm Gmbh Derivados de bis-MMF
CA2967908C (en) * 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
AU2014414316B2 (en) * 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
JP2017537088A (ja) * 2014-12-01 2017-12-14 セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited 多発性硬化症の治療のための組成物及び方法
CN116445137B (zh) * 2023-03-02 2024-08-16 西南石油大学 一种钻井液用改性碳球润滑剂及其制备方法及应用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA119916A (en) 1909-05-17 1909-08-10 Harry I. Lahr Car seal
US2807644A (en) 1954-08-20 1957-09-24 Parke Davis & Co Pantethine inhibitors
DE1205972B (de) 1963-08-20 1965-12-02 Merck Ag E Verfahren zur Herstellung eines Liponsaeure-derivates
US4011342A (en) 1971-06-02 1977-03-08 Seperic Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines
LU77306A1 (de) * 1977-05-09 1979-01-18
JPS5677259A (en) 1979-11-29 1981-06-25 Nippon Chemiphar Co Ltd N-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation
JPS57500432A (de) 1980-03-20 1982-03-11
US4404366A (en) 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en) 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
IT1190727B (it) 1982-03-10 1988-02-24 Ausonia Farma Srl Composto ad attivita' analgesica,antiinfiammatoria e mucoregolatrice procedimento per la sua preparazione e relative composizioni farmaceutiche
US4564628A (en) 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US5104887A (en) 1983-02-04 1992-04-14 University Of Iowa Research Foundation Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors
JPS6089474A (ja) 1983-10-20 1985-05-20 Toyo Pharma- Kk モルフイナン誘導体,その製造方法,及び該化合物を含有する抗腫瘍剤
IL73293A (en) 1983-11-04 1988-02-29 Abbott Lab Methyl 2-(alkanamidoalkylsulfonic)ethylthiophosphonate derivatives
IT1213132B (it) 1984-02-02 1989-12-14 Yason Srl Agente antibroncopneumopatico.
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5120738A (en) 1989-10-06 1992-06-09 Fujirebio Inc. Pantothenic acid derivatives
US5242937A (en) 1990-03-19 1993-09-07 Research Corporation Technologies, Inc. Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
IT1248702B (it) 1990-06-06 1995-01-26 Yason Srl Agente antitussivo e mucoregolatore,sua preparazione e composizioni farmaceutiche
FR2699077B1 (fr) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2707637B1 (fr) 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
JPH09511496A (ja) 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド 細胞内メッセンジャー
SE9401727D0 (sv) 1994-05-18 1994-05-18 Astra Ab New compounds I
FR2722199B3 (fr) 1994-07-11 1996-09-06 Univ Picardie Jules Verne Etab Derives de l'acide valproique et leurs applications comme medicaments
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
KR20000069075A (ko) 1996-11-22 2000-11-25 진 엠. 듀발 N-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
EP0968711B9 (de) 1997-10-28 2008-05-28 Bando Chemical Industries, Ltd. Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
NZ506574A (en) 1998-02-27 2003-06-30 Sankyo Co Cyclic amino derivative having a sulphinyl, sulphonyl or disulphanyl group useful in the treatment of thrombosis or embolism
JP3761324B2 (ja) 1998-05-15 2006-03-29 ヤンマー農機株式会社 乗用田植機
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
HUP0202797A3 (en) 1999-09-29 2004-05-28 Procter & Gamble Compositions having improved stability
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6602915B2 (en) 2000-07-27 2003-08-05 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
CA2426745C (en) 2000-10-24 2009-09-15 Ajinomoto Co., Inc. Methods for producing nateglinide b-type crystals
CZ304198B6 (cs) * 2001-01-12 2013-12-27 Fumapharm Ag Amidy kyseliny fumarové
DE10103506A1 (de) 2001-01-26 2002-08-14 Ingo S Neu Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
AU2002326806B2 (en) 2001-08-29 2007-07-19 Endo Pharmaceuticals, Inc. Analgetic pyrroline derivatives
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
AU2003242520A1 (en) 2002-04-15 2003-10-27 Novartis Ag Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
CN1646122A (zh) 2002-04-16 2005-07-27 藤泽药品工业株式会社 用于预防和/或治疗慢性排斥的药物
US7060725B2 (en) 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
GB0223224D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
CA2510455C (en) 2002-12-19 2013-03-12 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
NZ541733A (en) 2003-02-14 2009-03-31 Pf Medicament Use of the enantiomer (1S,2R) of milnacipran for the preparation of a medicament
UA81657C2 (ru) 2003-03-04 2008-01-25 Орто-Макнейл Фармасьютикел, Инк. Способ получения противосудорожных производных топирамата
CA2534342C (en) 2003-07-29 2016-05-10 V. Ravi Chandran Amino acid prodrugs
WO2005037784A2 (en) 2003-10-14 2005-04-28 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
MXPA06006035A (es) 2003-11-28 2007-01-26 Sankyo Co Derivado de amina ciclica que tiene un anillo heteroarilo.
DE10361259A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
CN1248690C (zh) 2004-03-25 2006-04-05 华中师范大学 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂
AU2005248294A1 (en) 2004-04-07 2005-12-08 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
AU2005244214B2 (en) 2004-04-29 2010-02-18 Teikoku Pharma Usa, Inc. Topical methadone compositions and methods for using the same
CN1672678A (zh) 2004-05-03 2005-09-28 深圳微芯生物科技有限责任公司 预防和治疗前列腺疾病的长链脂肪酸天然活性成分的分离、提取和药用制剂的制备和应用
ZA200610042B (en) 2004-06-04 2008-06-25 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
CN100455560C (zh) 2004-06-09 2009-01-28 中国人民解放军军事医学科学院放射医学研究所 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途
CA2600301A1 (en) 2005-03-18 2006-09-21 Ripped Formulations Ltd. Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition
EA200702358A1 (ru) 2005-05-11 2008-04-28 Никомед Гмбх Комбинация ингибитора pde4 и производного тетрагидробиоптерина
DE102005022276A1 (de) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
CA2626249A1 (en) 2005-10-18 2007-04-26 Boehringer Ingelheim International Gmbh Use of pramipexol for treating moderate to severe restless legs syndrome (rls)
KR20080091261A (ko) 2006-01-27 2008-10-09 아사히 가세이 파마 가부시키가이샤 경비 투여용 약제
WO2007121188A2 (en) 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
BG66222B1 (bg) 2006-06-08 2012-06-29 "Унифарм" Ад Диализен състав
EP1870395A1 (de) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Verfahren zur Herstellung von o-Desmethylvenlafaxin und seiner Analoga
US7943666B2 (en) 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CN100573950C (zh) 2006-12-14 2009-12-23 财团法人工业技术研究院 相变存储装置及其制造方法
AU2007333050B2 (en) 2006-12-14 2013-08-29 Knopp Biosciences Llc Compositions and methods of using (R)-pramipexole
AU2007338631A1 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
JP2010515747A (ja) 2007-01-12 2010-05-13 ビオマリン プハルマセウトイカル インコーポレイテッド テトラヒドロビオプテリンプロドラッグ
ES2319024B1 (es) 2007-02-13 2009-12-11 Quimica Sintetica, S.A. Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina.
EP2137171A4 (de) 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthese von chiralaufgereinigten substituierten benzothiazoldiaminen
CN102964302B (zh) 2007-05-01 2015-10-21 康塞特医药品公司 吗啡烷化合物
EP1997493A1 (de) 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Kombination aus einem 5-HT7-Rezeptor-Liganden und einem Opioidrezeptor-Liganden
EP2190853A4 (de) 2007-06-22 2011-08-31 Gluconova Llc Halogenidfreie komplexe aus glucosamin und einem sauren arzneimittel
US20090075942A1 (en) 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fosamprenavir
CN101390854A (zh) 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 一种含有利鲁唑的药用组合物
WO2009056791A1 (en) 2007-11-02 2009-05-07 Pliva Hrvatska D.O.O. Processes for preparing pharmaceutical compounds
TW200936123A (en) 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
CN101186583B (zh) 2007-12-20 2011-05-11 吉林大学 2-(2-(2,6-二氯苯基氨基)苯基)醋酸甲酯及其合成方法及其应用
US20100081713A1 (en) 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
CN101569618B (zh) 2008-04-30 2011-11-09 上海医药工业研究院 一类长链脂肪酸衍生物在制备预防或治疗前列腺增生疾病的药物组合物中的应用
KR100990949B1 (ko) 2008-06-09 2010-10-29 엔자이텍 주식회사 클로피도그렐 및 그의 유도체의 제조방법
CN104000808A (zh) 2008-07-08 2014-08-27 凯特贝希制药公司 脂肪酸乙酰化的水杨酸酯及其用途
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
NZ591326A (en) 2008-08-22 2012-12-21 Wockhardt Research Center An extended release pharmaceutical composition of entacapone or salts thereof
US20110313176A1 (en) 2008-12-26 2011-12-22 Actavis Group Ptc Ehf Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
BRPI0901298A2 (pt) 2009-04-06 2011-01-04 Ems Sa derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
CA2768877A1 (en) 2009-08-10 2011-02-17 Bellus Health Inc. Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
CN102002053A (zh) 2009-09-02 2011-04-06 陕西合成药业有限公司 用于治疗的四氢噻吩并吡啶衍生物
CN101717392A (zh) 2009-10-09 2010-06-02 苏州凯达生物医药技术有限公司 一种制备罗替戈汀及其衍生物的方法
CN102050815B (zh) 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 作为前药的达比加群的酯衍生物
CN101724934B (zh) 2009-11-10 2012-07-04 东华大学 一种用于治疗皮肤炎症和疼痛的药用纤维及其制备和应用
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
FR2954932A1 (fr) 2010-01-06 2011-07-08 Sarl Uni Distrib Systeme dehoussable de housse de selle de monocycle
MY160249A (en) 2010-01-08 2017-02-28 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
RU2436772C2 (ru) 2010-01-28 2011-12-20 Закрытое акционерное общество "НПК ЭХО" 4[(4'-никотиноиламино)бутироиламино]бутановая кислота, проявляющая ноотропную активность, и способ ее получения
WO2011106688A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
CN102947287A (zh) 2010-06-08 2013-02-27 M·坎杜拉 半胱胺衍生物及其在治疗非酒精性脂肪性肝炎中的用途
WO2012007352A1 (de) 2010-07-12 2012-01-19 Boehringer Ingelheim International Gmbh Wässrige zusammensetzung enthaltend bromhexin
WO2012025213A2 (en) 2010-08-23 2012-03-01 Grünenthal GmbH Novel therapeutic compounds
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
CN101921245B (zh) 2010-08-30 2012-04-18 中国人民解放军军事医学科学院卫生学环境医学研究所 抑制碳酸酐酶ⅱ的磺胺类化合物及合成方法与用途
DK2632451T3 (en) 2010-10-29 2017-12-18 Algiax Pharmaceuticals Gmbh USE OF MALONNITRILAMIDS IN NEUROPATHIC PAIN
EP2450039A1 (de) 2010-11-08 2012-05-09 PAION UK Ltd. Dosierschema zur Sedierung mit CNS 7056 (Remimazolam)
WO2012115695A1 (en) 2011-02-25 2012-08-30 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2013008182A1 (en) 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
CN102336767A (zh) 2011-07-11 2012-02-01 华东理工大学 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法
WO2013017974A1 (en) 2011-07-30 2013-02-07 Mahesh Kandula Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013024376A1 (en) 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
WO2013027150A1 (en) 2011-08-21 2013-02-28 Mahesh Kandula Compositions and methods for the treatment of parkinson's disease
CN102633799B (zh) 2012-04-10 2014-06-25 凯莱英医药集团(天津)股份有限公司 一种从消旋体中间体拆分路线合成二盐酸沙丙蝶呤的方法
WO2013167988A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of cough
WO2013168022A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013167996A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
ES2731837T3 (es) * 2012-12-21 2019-11-19 Ratiopharm Gmbh Profármacos de fumarato de monometilo (MMF)

Also Published As

Publication number Publication date
AU2013264896A1 (en) 2014-11-27
WO2013175359A3 (en) 2014-02-20
US20160122291A1 (en) 2016-05-05
ZA201408062B (en) 2016-04-28
WO2013175359A2 (en) 2013-11-28
US9580383B2 (en) 2017-02-28
JP2015518854A (ja) 2015-07-06
CA2873098A1 (en) 2013-11-28
CN104603097A (zh) 2015-05-06
EP2852569B1 (de) 2020-10-14
EP2852569A2 (de) 2015-04-01
EP2852569A4 (de) 2015-12-02

Similar Documents

Publication Publication Date Title
SG11201407326XA (en) Compositions and methods for treatment of mucositis
SG11201408094YA (en) Neprilysin inhibitors
SG11201408739VA (en) Inhibitors of hepatitis c virus
SG11201407323WA (en) Compositions and methods for the treatment of local pain
SG11201407303SA (en) Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201407115XA (en) Carboxylic acid compounds
SG11201407411SA (en) Compositions and methods for the treatment of metabolic syndrome
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201407533SA (en) Antiviral compounds
SG11201408539UA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201407537YA (en) Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
SG11201407319YA (en) Compositions and methods for treatment of inflammatory bowel disease
SG11201408261UA (en) Syringe
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201407189XA (en) C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201407322QA (en) Compositions and methods for the treatment of multiple sclerosis
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201407337QA (en) Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
SG11201810294QA (en) Treatment for parkinson's disease
SG11201805649UA (en) Therapeutic anti-cd9 antibody